Bayer is backing up its move into the cell therapy category led by subsidiary BlueRock Therapeutics with a $250 million investment in a new manufacturing facility in Berkeley, California.

The start of trials is a milestone for Bayer's ambition to develop cell and gene-based therapies for Parkinson's that could replace the dopamine-producing neurons in the midbrain area that are ...

Bayer UK launches new CanesMeno Educational Hub and product range to transform menopause support: Leverkusen Friday, January ...